Filed: 10/30/2024ACC: 0001104659-24-112539
📋 What this filing means
RIVERVEST VENTURE MANAGEMENT LLC filed this quarterly 13F‑HR report disclosing 3 equity positions with a total reported market value of $6.84M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
3
Positions
$6.84M
Total AUM (reported)
6.91M
Total Shares
Allocation by class
COMMON$6.84M100.0%
Portfolio Concentration
Top 3$6.84M100.0%
Top 3 weight
100.0%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 6.91M
Sole
Full voting authority
6.91M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole3
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings3
Rows:
Reneo Pharmaceuticals, Inc.
SOLEShares2.53M
TypeSH
Market value$4.31M
63.00%
Sole
2.53M
Shared
0.00
None
0.00
Spruce Bioscience, Inc.
SOLEShares2.94M
TypeSH
Market value$1.39M
20.39%
Sole
2.94M
Shared
0.00
None
0.00
Xilio Therapeutics, Inc.
SOLEShares1.44M
TypeSH
Market value$1.14M
16.60%
Sole
1.44M
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Reneo Pharmaceuticals, Inc.SOLE | Common | 2.53M | SH | $4.31M 63.00% | 2.53M | 0.00 | 0.00 |
Spruce Bioscience, Inc.SOLE | Common | 2.94M | SH | $1.39M 20.39% | 2.94M | 0.00 | 0.00 |
Xilio Therapeutics, Inc.SOLE | Common | 1.44M | SH | $1.14M 16.60% | 1.44M | 0.00 | 0.00 |